Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of ITIL-306 in Advanced Solid Tumors
NCT05397093Phase 1Terminated
- Sponsor
- Instil Bio, Inc.
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of ITIL-306 in epithelial ovarian cancer (EOC), non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (2 arms), sponsored by Instil Bio, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 24 months. Started Aug 2022; status: terminated.
02
Drugs
ITIL-306
03
Conditions
epithelial ovarian cancer (EOC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05397093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397093.